

CHINA PHARMA HOLDINGS, INC.
Form 10-Q
November 14, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from _____ to _____

Commission File Number 001-34471

CHINA PHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10-Q

Nevada 75-1564807
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)

Second Floor, No. 17, Jinpan Road

Haikou, Hainan Province, China 570216

(Address of principal executive offices) (Zip Code)

+86- 898-6681-1730 (China)

(Issuer's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	Accelerated filer
Non-accelerated filer	(Do not check if a smaller reporting company) Smaller reporting company
	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 43,579,557 shares of Common Stock, \$.001 par value, were outstanding as of November 10, 2017.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

	Page
PART I FINANCIAL INFORMATION	
Item 1. Financial Statements	1
Condensed Consolidated Balance Sheets as of September 30, 2017 (Unaudited) and December 31, 2016 (Audited)	F-2
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2017 and 2016 (Unaudited)	F-3
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (Unaudited)	F-4
Notes to Condensed Consolidated Financial Statements (Unaudited)	F-5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	2
Item 3. Quantitative and Qualitative Disclosures about Market Risk	13
Item 4. Controls and Procedures	13
PART II OTHER INFORMATION	
Item 6. Exhibits	14

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited condensed consolidated balance sheets, statements of operations and comprehensive income, and statements of cash flows and the related notes thereto, have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the disclosures required by U.S. GAAP for complete financial statements. The financial statements reflect all adjustments, consisting only of normal, recurring adjustments, which are, in the opinion of management, necessary for a fair presentation for the interim periods.

The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2016.

The results of operations for the nine-month period ended September 30, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or any other period.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

Condensed Consolidated Balance Sheets as of September 30, 2017 (Unaudited) and December 31, 2016 (Audited)	F-2
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2017 and 2016 (Unaudited)	F-3
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (Unaudited)	F-4
Notes to Condensed Consolidated Financial Statements (Unaudited)	F-5

F-1

CHINA PHARMA HOLDINGS, INC.**CONDENSED CONSOLIDATED BALANCE SHEETS**

	September 30, 2017 (Unaudited)	December 31, 2016 (Audited)
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 1,124,439	\$ 2,665,802
Restricted cash	1,380,509	1,088,879
Bankers acceptance notes	22,920	-
Trade accounts receivable, less allowance for doubtful accounts of \$17,641,435 and \$15,664,496, respectively	2,908,517	3,999,809
Other receivables, less allowance for doubtful accounts of \$55,795 and \$71,548, respectively	177,002	224,373
Advances to suppliers	2,387,356	2,003,792
Inventory	6,828,532	7,310,939
Prepaid expenses	168,115	226,357
Total Current Assets	14,997,390	17,519,951
Advances for purchases of intangible assets	35,414,977	35,498,059
Property, plant and equipment, net	24,153,087	24,967,448
Intangible assets, net	429,052	534,682
TOTAL ASSETS	\$ 74,994,506	\$ 78,520,140
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current Liabilities:		
Trade accounts payable	\$ 1,890,927	\$ 3,060,374
Accrued expenses	321,005	139,830
Other payables	2,560,631	2,502,694
Advances from customers	585,041	811,232
Other payables - related parties	1,354,567	1,354,567
Current portion of construction loan facility	2,292,001	1,440,154
Banker's acceptance notes payable	1,380,509	1,088,879
Total Current Liabilities	10,384,681	10,397,730
Non-current Liabilities:		
Construction loan facility	6,876,003	8,640,927
Deferred tax liability	703,044	572,349
Total Liabilities	17,963,728	19,611,006
Stockholders' Equity:		
Preferred stock, \$0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	-	-
Common stock, \$0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively	43,580	43,580

Edgar Filing: CHINA PHARMA HOLDINGS, INC. - Form 10-Q

Additional paid-in capital	23,590,204	23,590,204
Retained earnings	19,307,138	24,757,374
Accumulated other comprehensive income	14,089,856	10,517,976
Total Stockholders' Equity	57,030,778	58,909,134
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	\$ 74,994,506	\$ 78,520,140

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-2

CHINA PHARMA HOLDINGS, INC.**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS****AND COMPREHENSIVE LOSS****(Unaudited)**

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2017	2016	2017	2016
Revenue	\$3,162,222	\$3,125,596	\$9,364,605	\$10,308,320
Cost of revenue	2,740,683	2,775,628	7,576,856	8,835,436
Gross profit	421,539	349,968	1,787,749	1,472,884
Operating expenses:				
Selling expenses	686,825	927,187	2,207,896	2,753,388
General and administrative expenses	348,963	294,367	1,377,640	1,394,250
Research and development expenses	27,543	99,095	75,053	289,189
Bad debt expense	229,466	(69,899)	954,518	1,005,949
Impairment of long term assets	1,184,103	644,696	2,162,083	1,467,235
Total operating expenses	2,476,900	1,895,446	6,777,190	6,910,011
Subsidy income	-	(2,325)	-	346,347
Loss from operations	(2,055,361)	(1,547,803)	(4,989,441)	(5,090,780)
Other income (expense):				
Interest income	21,947	32,434	43,296	99,149
Interest expense	(130,816)	(213,740)	(411,985)	(699,932)
Net other expense	(108,869)	(181,306)	(368,689)	(600,783)
Loss before income taxes	(2,164,230)	(1,729,109)	(5,358,130)	(5,691,563)
Income tax expense	(31,198)	(20,800)	(92,106)	(65,044)
Net loss	(2,195,428)	(1,749,909)	(5,450,236)	(5,756,607)
Other comprehensive income (loss) - foreign currency translation adjustment	2,083,398	(275,928)	3,571,880	(1,949,137)
Comprehensive loss	\$(112,030)	\$(2,025,837)	\$(1,878,356)	\$(7,705,744)
Loss per share:				
Basic and Diluted	\$(0.05)	\$(0.04)	\$(0.13)	\$(0.13)
Weighted average shares outstanding	43,579,557	43,579,557	43,579,557	43,579,557

The accompanying notes are an integral part of these condensed consolidated financial statements.

CHINA PHARMA HOLDINGS, INC.**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(Unaudited)**

For the Nine Months
Ended September 30,
2017 2016

Cash Flows from Operating Activities:		
Net loss	\$(5,450,236)	\$(5,756,607)
Depreciation and amortization	2,447,866	2,583,066
Bad debt expense	954,518	1,005,949
Deferred income taxes	92,106	65,044
Impairment of long-term assets	2,162,083	1,467,235
Changes in assets and liabilities:		
Trade accounts and other receivables	21,325	(709,257)
Advances to suppliers	(251,306)	(150,606)
Inventory	1,237,573	1,627,641
Trade accounts payable	(1,303,944)	739,551
Accrued taxes payable	1,719	(74,080)
Other payables and accrued expenses	188,557	119,085
Advances from customers	(265,092)	432,904
Prepaid expenses	69,284	71,790
Net Cash (Used in) Provided by Operating Activities	(95,547)	1,421,715
Cash Flows from Investing Activities:		
Purchases of property, plant and equipment	(67,324)	(86,350)
Net Cash Used in Investing Activities	(67,324)	(86,350)
Cash Flows from Financing Activities:		
Payments of construction term loan	(1,469,349)	(1,519,932)
Payments of short term debt	-	(2,279,899)
Net Cash Used in Financing Activities	(1,469,349)	(3,799,831)
Effect of Exchange Rate Changes on Cash	90,857	(134,255)
Net (Decrease) Increase in Cash and Cash Equivalents	(1,541,363)	(2,598,721)
Cash and Cash Equivalents at Beginning of Period	2,665,802	6,248,760
Cash and Cash Equivalents at End of Period	\$1,124,439	\$3,650,039
Supplemental Cash Flow Information:		
Cash paid for income taxes	\$-	\$-
Cash paid for interest	410,509	689,773
Supplemental Noncash Investing and Financing Activities:		
Accounts receivable collected with banker's acceptance notes	366,889	803,655
Inventory purchased with banker's acceptance notes	344,848	781,814

Issuance of banker's acceptance notes	126,652	1,490,154
---------------------------------------	---------	-----------

The accompanying notes are an integral part of these consolidated financial statements.

F-4

CHINA PHARMA HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)

NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Operations – China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People’s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.

On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012. The reincorporation merger was approved by stockholders holding the majority of the Company’s outstanding shares of common stock on December 21, 2012.

The Foreign Investment Industrial Catalogue (the “Catalogue”) jointly issued by China’s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2017 version, effective June 30, 2017) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the “FIE”) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company’s business.

Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson’s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.

The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.

Consolidation and Basis of Presentation – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.

Helpson's functional currency is the Chinese Renminbi. Helpson's revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson's financial statements are included in accumulated other comprehensive income, which is a component of stockholders' equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.

Accounting Estimates - The methodology used to prepare for the Company's financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company ("Management") to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.

Cash and Cash Equivalents – Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker's acceptance notes purchased with maturities of three months or less.

Restricted Cash –Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes issued by the Company as discussed in Note 7.

Trade Accounts Receivable and Allowance for Doubtful Accounts – Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled \$229,466 and (\$69,899) for the three months ended September 30, 2017 and 2016, respectively and \$954,518 and \$1,005,949 for the nine months ended September 30, 2017 and 2016, respectively.

Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of \$0 against the allowance for both the nine months ended September 30, 2017 and 2016, respectively. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.

F-5

CHINA PHARMA HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)

Advances to Suppliers and Advances from Customers – Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized no bad debt expense for the nine months ended September 30, 2017 and 2016, respectively.

Inventories – Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company's production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicible costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.

Valuation of Long-Lived Assets – The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. During the three months ended September 30, 2017 and 2016 the Company recognized an impairment related to Advances for purchases of intangible assets in the amount of \$1,184,103 and \$644,696. During the nine months ended September 30, 2017 and 2016 the Company recognized an impairment related to Advances for purchases of intangible assets in the amount of \$2,162,083 and \$1,467,235 respectively as more fully discussed in Note 5.

Property, Plant and Equipment – Property, plant and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or

retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.

Revenue Recognition – Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured.

Cost of Revenues – Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.

Research and Development – Research and development expenditures are recorded as expenses in the period in which they occur.

Basic and Diluted Loss per Common Share - Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares. There were no potential dilutive common shares outstanding during the three and nine months ended September 30, 2017 and 2016, respectively.

Credit Risk – The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.

The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors' interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June 1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company's deposits may be at a higher risk of loss.

Interest Rate Risk – The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.

Reclassification – Certain amounts were reclassified in the presentation of the prior period amounts to conform to the current period presentation.

F-6

CHINA PHARMA HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, “*Revenue from Contracts with Customers*” (ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.

The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on its financial statements.

In February 2016, the FASB issued ASU No. 2016-02, *Leases*, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB’s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.

In June 2016, the FASB issued Accounting Standards Update 2016-13, *Financial Instruments – Credit Losses (Topic 326)*, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a

simplified accounting model for purchased financial assets with credit deterioration since their origination. The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early application of the guidance will be permitted for all entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU No. 2016-15, *Classification of Certain Cash Receipts and Cash Payments*. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.

In November 2016, the FASB issued ASU 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash* (“ASU 2016-18”). The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.

From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its condensed consolidated financial statements upon adoption.

CHINA PHARMA HOLDINGS, INC.**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)****NOTE 2 – INVENTORY**

Inventory consisted of the following:

	September 30, 2017	December 31, 2016
Raw materials	\$ 10,873,118	\$ 11,562,388
Work in process	316,510	360,550
Finished goods	1,838,017	1,530,641
	13,027,645	13,453,579
Obsolescence reserve	(6,199,113)	(6,142,640)
Total Inventory	\$ 6,828,532	\$ 7,310,939

NOTE 3 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:

	September 30, 2017	December 31, 2016
Permit of land use	\$ 430,388	\$ 405,645
Building	9,994,281	9,419,700
Plant, machinery and equipment	27,814,173	26,151,029
Motor vehicle	328,673	309,777
Office equipment	195,886	182,718
Total	38,763,401	36,468,869
Less: accumulated depreciation	(14,610,314)	(11,501,421)
Property, Plant and Equipment, net	\$ 24,153,087	\$ 24,967,448

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset	Life - years
Permit of land use	40 - 70
Building	20 - 49
Plant, machinery and equipment	5 - 10
Motor vehicle	5 - 10
Office equipment	3-5

Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended June 30, 2017 and 2016, depreciation expense was \$779,856 and \$789,150, respectively. For the six months ended June 30, 2017 and 2016, depreciation expense was \$2,314,928 and \$ 2,383,457, respectively.

NOTE 4 - INTANGIBLE ASSETS

Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (“CFDA”). The Company did not obtain CFDA production approval for any medical formula during the six months ended June 30, 2017 and 2016 and no costs were reclassified from advances to intangible assets during the six months ended June 30, 2017 and 2016, respectively.

Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was \$39,630 and \$65,643, respectively for the three months ended September 30, 2017 and 2016 and \$132,938 and \$199,609 for the nine months ended September 30, 2016 and 2015, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.

CHINA PHARMA HOLDINGS, INC.**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)**

The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company's evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company's estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the nine months ended September 30, 2017 and 2016.

Intangible assets consisted solely of CFDA approved medical formulas as follows:

	September 30, 2017	December 31, 2016
Gross carrying amount	\$ 5,158,323	\$ 4,861,766
Accumulated amortization	(4,729,271)	(4,327,084)
Net carrying amount	\$ 429,052	\$ 534,682

NOTE 5 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS

In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.

Prior to entering into contracts with the Company, laboratories typically are required to complete all research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the

CFDA.

A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA's approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date the Company signs the medical formula contracts.

Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.

During the nine months ended September 30, 2017, the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that the advances made by the Company for three formulas to two of the independent laboratories were impaired. In the same period in 2016, the company recognized an impairment loss for the advances made to three laboratories for one formula. The Company recognized impairment losses in the amount of \$1,184,103 and 644,696 for the three months ended September 30, 2017 and 2016, respectively. Impairment loss was \$2,162,083 and \$1,467,235 for the nine months ended September 30, 2017 and 2016, respectively.

As of September 30, 2017, the Company was obligated to pay laboratories and others approximately \$2,800,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.

NOTE 6 – RELATED PARTY TRANSACTIONS

A member of the Company's board of directors had previously advanced the Company an aggregate amount of \$1,354,567 as of September 30, 2017 and December 31, 2016 which are recorded as Other payables – related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest

expense for the three months ended September 30, 2017 and 2016 was \$3,386 and \$3,386. Total interest expense for the nine months ended September 30, 2017 and 2016 was \$10,159 and \$10,159, respectively.

F-9

CHINA PHARMA HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)

NOTE 7 – BANKER’S ACCEPTANCE NOTES PAYABLE

In April 2016, the Company entered into a Banker’s Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker’s acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the banker’s acceptance notes issued to the third parties. The amount of these deposited balances is shown as “Restricted cash” on the accompanying balance sheets as of September 30, 2017 and December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately \$4.5 million) or the amount of cash available to deposit against the banker’s acceptance notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. At September 30, 2017 and December 31 2016, the Company had outstanding banker’s acceptance notes in the amount of \$1,380,509 and \$1,088,879, respectively.

NOTE 8 – CONSTRUCTION LOAN FACILITY

The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately \$13 million) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipment and machinery. At June 30, 2017, the loan bears weighted interest at 5.73%, based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94% and on July 10, 2016 the rate was further adjusted to 5.39%. The loan required interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments with the first annual payment being due within the six-month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. During the nine months ended September 30, 2017, the Company made principal payments in the amount of approximately \$1,469,000 (RMB10,000,000). As of September 30, 2017, the Company had no additional amounts available to it under this facility.

Principal payments required for the next five years as of September 30, 2017 are as follows:

Twelve Months Ending September 30,	Amount
2018	2,292,001
2019	2,292,001
2020	2,292,001
2021	2,292,001
	\$9,168,004

Fair Value of Construction Loan Facility – Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of September 30, 2017 and December 31, 2016 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.

NOTE 9 - INCOME TAXES

Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.

Undistributed earnings of Helpson, the Company's foreign subsidiary, since its acquisition, amounted to approximately \$26.3 million as of September 30, 2017. Those earnings, as well as the investment in Helpson of approximately \$23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.

CHINA PHARMA HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)

Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through September 30, 2017, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income tax return for the year ended December 31, 2016 are open for possible examination.

On March 16, 2007, the National People’s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January 1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.

The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016. The recent net losses put the Company in an unfavorable position for the potential renewal of “National High-Tech Enterprise” status for 2017. After evaluating the feasibility of the renewal in 2016, the Company has decided not to renew this status. Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:

Year	Enterprise Income Tax Rate
2015	15%
2016	15%
Thereafter	25%

The provision for income taxes consisted of the following:

	Three Months		Nine Months	
	Ended		Ended	
	September 30,		September 30,	
	2017	2016	2017	2016
Current	\$-	\$-	\$-	\$-
Deferred	31,198	20,800	92,106	65,044
Total income tax expense	\$31,198	\$20,800	\$92,106	\$65,044

As of September 30, 2017, the Company had net operating loss carryforwards for PRC tax purposes of approximately \$56.7 million which are available to offset any future taxable income through 2022. These carryforwards begin to expire in 2018. The Company also has net operating losses for United States federal income tax purposes of approximately \$4.8 million which are available to offset future taxable income, if any, through 2037.

In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of September 30, 2017 and December 31, 2016. Therefore, the Company provided for a valuation allowance against its deferred tax assets of \$24,267,042 and \$21,452,802 as of September 30, 2017 and December 31, 2016, respectively.

The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

NOTE 10 – FAIR VALUE MEASUREMENTS

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

F-11

CHINA PHARMA HOLDINGS, INC.**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS****THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2017 AND 2016 (UNAUDITED)**

The Company uses fair value to measure the value of the banker's acceptance notes it holds. The banker's acceptance notes are recorded at cost which approximates fair value. As of December 31, 2016, the Company had no banker's acceptance notes to be recorded at fair value. The Company held the following assets and liabilities recorded at fair value as of September 30, 2017:

Description	September 30, 2017	Fair Value Measurements at Reporting Date Using		
		Level 1	Level 2	Level 3
Banker's acceptances	\$ 22,920	\$ -	\$22,920	\$ -
Total	\$ 22,920	\$-	\$22,920	\$-

NOTE 11 - STOCKHOLDERS' EQUITY

The Company is authorized to issue 95,000,000 shares of common stock, \$0.001 par value, and 5,000,000 shares of preferred stock, \$0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company's Board.

Employee Stock Options*2010 Incentive Plan*

On November 12, 2010, the Company's Board of Directors adopted the Company's 2010 Incentive Plan (the "Plan"), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through September 30, 2017, there were 175,000 shares of restricted stock granted and outstanding under the Plan. No options were

outstanding as of September 30, 2017 under the Plan.

There were no securities issued from the Plan during each of the nine months ended September 30, 2017 and 2016.

The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the nine months ended September 30, 2017 and 2016.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company's common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

As of September 30, 2017, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

NOTE 12 – COMMITMENTS AND CONTINGENCIES

Economic environment - Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company's operations.

In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

NOTE 13 – CONCENTRATIONS

For the nine months ended September 30, 2017, no customer accounted for more than 10% of sales and two customers accounted for 47% and 14% of accounts receivable, respectively. Four suppliers accounted for 21.1%, 17.4%, 15.3% and 14.7% of raw material purchases.

For the nine months ended September 30, 2016, no customer accounted for more than 10% of sales and one supplier accounted for 21.7% of raw material purchases. At September 30, 2016, three customers accounted for 28.3%, 11.3% and 11% of accounts receivable, respectively.

F-12

In order to support our existing products package we remain focused on pipeline development. However, we have experienced delays in obtaining approval for certain products in our pipeline because of revisions of and enhancements to CFDA approval criteria and processes required by CFDA. These revisions have resulted in additional supplemental materials and trials, higher costs, and longer approval times for certain applications.

On March 5, 2016, the Chinese State Council issued “*Opinions on Carrying out Consistency Evaluations of the Quality and Efficacy of Generic Drugs*” (the “Opinions”). The Opinions define the object of evaluations and establish deadlines, determine selection criteria for reference drugs, call for a rational selection of evaluation methods, identify pharmaceutical manufacturers as the principle in generic drug consistency evaluations, and set forth corresponding incentives. In May, 2016, the CFDA issued “*Comments from the General Office of the State Council on the Consistency Evaluations of the Efficacy and Quality of Generic Drugs*” in order to further elaborate on assessment processes and related technical rules. Consistency evaluations apply to the majority of our current existing marketed and pipeline products. Complying with consistency evaluations will become our core task in the near future and will have a significant impact on our operations as well as our industrial structure.

As a result, the status of our pipeline products as of September 30, 2017 remains the same as we reported in our Annual Report on Form 10-K for the year ended December 31, 2016.

Market Trends

Consumer demand for medicine is relatively rigid and stable and is generally unaffected by seasonal business cycles. We have noticed that the growth rates of the pharmaceutical manufacturing industry have been higher than GDP growth rates in China. According to the study “*Deepening The Reform of China’s Medical and Healthcare System and Building A Value-Based Quality Service Delivery System*” published by the World Bank, if China maintains its existing healthcare system, total health expenditures will increase from 5.5% of GDP in 2014 to over 9% of GDP in 2035, with an average annual growth rate of 8.4%.

The rapid development of the pharmaceutical industry in China has been driven by the continuous growth of total healthcare costs, the establishment and improvement of the universal Medicare system, increases in medical expenditures per capita, the aging population, and changes in the disease spectrum; however, development has been negatively impacted by factors like Medicare cost controls and price pressure in drug tenders in recent years.

The PRC State Council issued “*Guidance on the Pilot Comprehensive Reform of Urban Public Hospitals*” in 2015, which proposed that the pilot comprehensive reform of urban public hospitals be fully implemented and that the personal spending component of total hygiene expenditures be reduced to 30% or lower by 2017. In order to achieve

this goal, the Chinese government's ongoing investment will be essential. The Central Committee Political Bureau of the Communist Party of China approved the "Healthy China 2030 Plan" in August 2016, which proposed to reduce personal hygiene spending to approximately 28% of total healthcare expenditures by 2020, and 25% of total healthcare expenditures by 2030.

In order to achieve the objectives of the above-mentioned “Healthy China 2030 Plan” in the context of an aging population and an improving universal Medicare system, we believe that the hygiene spending proportion of total fiscal expenditures will increase and that net annual Medicare expenditures will increase as well. We anticipate that the use of generic drugs as a cost-effective medical solution will be further promoted as a way to reduce the payment pressures of Medicare. As a generic drug company, we are presented with a huge domestic market, and through further upgrades, especially in regards to compliance with consistency evaluations, we could meet European and American production standards, enabling us to engage overseas markets through product exports.

In general, demand for pharmaceutical products is still experiencing steady growth in China. We will continue to actively adapt to state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimize our development strategy.

Results of Operations for the Three Months Ended September 30, 2017 and 2016

Under the industrial reform and modification background guided by the government’s healthcare reform policies, we have actively completed the new GMP upgrades for the majority of our current production facilities, and have been aggressively promoting our sales to regain our original market shares. Although there was no immediate reversal of sales trends so far, due to the special characteristics of pharmaceutical industry, we strongly believe that our current operations and financial position will allow us to have a foundation for steady business growth in the future.

Net loss for the three months ended September 30, 2017 was \$2.2 million, compared to net loss of \$1.7 million for three months ended September 30, 2016. The difference in performance between the third quarters in 2017 and 2016 was mainly due to the increase in impairment of long term assets in the three months ended September 30, 2017, compared to the same period in 2016.

Revenue

Revenues were \$3.2 million and \$3.1 million for the three months ended September 30, 2017 and 2016 respectively.

Sales Revenue by Major Category (Dollars in Millions)

Set forth below are our revenues by product category in millions USD for the three months ended September 30, 2017 and 2016:

Product Category	Three Months Ended September 30,		Net	%	
	2017	2016	Change	Change	
CNS Cerebral & Cardio Vascular	0.48	0.57	-0.09	-16	%
Anti-Viro/ Infection & Respiratory	1.67	1.78	-0.11	-6	%
Digestive Diseases	0.31	0.22	0.09	41	%
Other	0.70	0.56	0.14	25	%

The most significant revenue decrease in terms of dollar amount was in our “Anti-Viro/Infection & Respiratory” category which has decreased by \$0.11 million to \$1.67 million in the third quarter of 2017 as compared to \$1.78 million in the same period of 2016, which was mainly affected by the sales decrease of Cefaclor due to market fluctuation.

The “Other” product category generated \$0.70 million in sales revenue in the third quarter of 2017, as compared to \$0.56 million in the same period of 2016, an increase of \$0.14 million. This increase was mainly due to the increase in sales of Vitamin B6 due to market fluctuation.

Our “Digestive Diseases” category generated \$0.31 million of sales in the third quarter of 2017 as compared to \$0.22 million in the same period of the previous year, which represented an increase of \$0.09 million.

Sales in our “CNS Cerebral & Cardio Vascular” category generated \$0.48 million in sales revenue in the third quarter of 2017 as compared to \$0.57 million in the same period of 2016, a decrease of \$0.09 million.

**Three
Months
Ended**

Product Category	September	
	30,	
	2017	2016
CNS Cerebral & Cardio Vascular	15 %	18 %
Anti-Viro/ Infection & Respiratory	53 %	57 %
Digestive Diseases	10 %	7 %
Other	22 %	18 %

For the three months ended September 30, 2017, revenue breakdown by product category remained comparable to that of the prior year. Sales of the “Anti-Viro/Infection & Respiratory” products category represented 53% and 57% of total sales in the three months ended September 30, 2017 and 2016. The “Other” category represented 22% and 18% of total sales in the three months ended September 30, 2017 and 2016. The “CNS, Cerebral & Cardio Vascular” category represented 15% and 18% of total sales in the three months ended September 30, 2017 and 2016. The “Digestive Diseases” category represented 10% of total revenue in the third quarter of 2017 compared to 7% in the third quarter of 2016.

Cost of Revenue

For the three months ended September 30, 2017, our cost of revenue was \$2.7 million, or 86.7% of total revenue, and \$2.8 million, or 88.8% of total revenue, in the same period of 2016.

Gross Profit and Gross Margin

Gross profit was \$0.4 million and \$0.3 million for the three months ended September 30, 2017 and 2016, respectively. Our gross profit margin in the third quarter of 2017 was 13.3% compared to 11.2% in the same period 2016.

Selling Expenses

Our selling expenses for the three months ended September 30, 2017 were \$0.7 million, which accounted for 21.7% of the total revenue in the third quarter of 2017, compared to \$1.0 million for the same period 2016, which accounted for 29.7% of the total revenue in the third quarter of 2016. Due to many adjustments in our selling processes under healthcare reform policies, despite the decrease in sales, we still need to maintain personnel and continue our sales activities to support the sales and collection of accounts receivable, therefore our selling expenses did not decrease proportionally to our sales.

General and Administrative Expenses

Our general and administrative expenses for the three months ended September 30, 2017 and September 30, 2016, were both \$0.3 million. General and administrative expenses accounted for 11.0% and 9.4% of our total revenues in the third quarters of 2017 and 2016, respectively.

Research and Development Expenses

Our research and development expenses were \$0.03 million and \$0.1 million for the three months ended September 30, 2017 and 2016, respectively. Research and development expenses accounted for 0.9% and 3.2% of our total

revenues in the third quarters of 2017 and 2016, respectively.

Bad Debt Expense (Benefit)

Our bad debt expense for the three months ended September 30, 2017 was \$0.2 million, compared to a bad debt benefit of \$0.1 million in the three months ended September 30, 2016. The change was due to the increase of aged accounts receivables.

In general, our regular credit or payment terms offered to customers are 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors who sell our products to mostly government-backed hospitals. Therefore, the aging of our receivables from our customers tend to be long.

The amount of accounts receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was \$2.8 million and \$3.6 million as of September 30, 2017 and December 31, 2016, respectively.

The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016	
1 - 90 Days	3.0	%	8.8	%
90 - 180 Days	1.9	%	2.6	%
180 - 360 Days	7.3	%	6.7	%
360 - 720 Days	10.6	%	13.4	%
> 720 Days	77.2	%	68.5	%
Total	100.0	%	100.0	%

Our bad debt allowance estimate is currently the sum of 10% of accounts receivable that are less than 365 days old, 70% of accounts receivable that are between 365 days and 720 days old and 100% of accounts receivable that are greater than 720 days old.

We recognize bad debt expense per actual write-offs as well as the changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was \$17.6 million and \$15.7 million as of September 30, 2017 and December 31, 2016, respectively.

Impairment of Long-Term Assets

During the third quarter of 2017 the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that advances made by the Company for two formulas to two independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to these laboratories in the amount of \$1.2 million. In the same period in 2016, the Company also recognized \$0.6 million impairment loss for the advances made to one laboratory for one formula per the evaluation.

Loss from Operations

Our operating loss for the three months ended September 30, 2017 was \$2.1 million, compared to \$1.5 million in the same period 2016. The operating loss for this period is mainly due to the increase in impairment of long term assets.

Interest Expense

Interest expense for the three months ended September 30, 2017 was \$0.1 million, compared to \$0.2 million in the same period 2016, which represented a decrease of \$0.1 million.

Income Tax Expense

Our income tax rate was 25% for the three months ended September 30, 2017, and 15% for the three months ended September 30, 2016. Our income tax expense was (\$0.03) million and (\$0.02) million for the three months ended September 30, 2017 and 2016, respectively. The expense arose as a result of certain deferred tax liabilities recognized in prior years. We renewed our “National High-Tech Enterprise” status with the Chinese government in the third quarter of 2013. With this designation, for the years ending December 31, 2015 and 2016, we enjoyed a preferential tax rate of 15%, which is notably lower than the statutory income tax rate of 25%. However, our recent net loss results have put the Company in an unfavorable position for the potential renewal of “National High-Tech Enterprise” status in 2017, and after evaluating the feasibility of such a renewal, the Company has decided not to renew this status. As a result, our tax rate for 2017 and the foreseeable future will be 25%.

Net Loss

Net loss for three months ended September 30, 2017 was \$2.2 million, compared to net loss of \$1.7 million for the three months ended September 30, 2016. The change in the net result was mainly due to the increase in impairment of long term asset in the third quarter of 2017 as compared to the same period of 2016.

For the three months ended September 30, 2017, loss per basic and diluted common share was \$0.05, compared to \$0.04 for the three months ended September 30, 2016.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 43,579,557 for both the three months ended September 30, 2017 and 2016.

Results of Operations for the nine months ended September 30, 2017 and 2016

Revenue

For the nine months ended September 30, 2017, our sales revenue was \$9.4 million, which represented a decrease of \$0.9 million, or 9.2%, from the \$10.3 million in the corresponding period of 2016. This decrease was primarily due to the decrease in sales of Cefaclor and Gastrodin.

Set forth below are our revenues by product categories in millions USD for each of the nine months ended September 30, 2017 and 2016.

Sales Revenue by Major Category (Dollars in Millions)

Product Category	Nine Months Ended September 30,		Net	%	
	2017	2016	Change	Change	
CNS Cerebral & Cardio Vascular	1.41	1.78	-0.37	-21	%
Anti-Viro/ Infection & Respiratory	5.75	6.76	-1.01	-15	%
Digestive Diseases	0.61	0.58	0.03	5	%
Other	1.60	1.19	0.41	34	%

The most significant decrease in revenue in terms of dollar amount was in our “Anti-Viro/ Infection & Respiratory” product category, which generated \$5.75 million in sales revenue in the nine months ended September 30, 2017, compared to \$6.76 million in the nine months ended September 30, 2016, a decrease of \$1.01 million. This decrease was mainly caused by the decrease in sales of Cefactor due to market fluctuation.

“Other” category increased by \$0.41 million to \$1.60 million in the nine months ended September 30, 2017 compared to \$1.19 million in the same period of 2016 and the increase was mainly due to the sales increase in Vitamin B6 for Injection due to market fluctuation.

Our “CNS Cerebral & Cardio Vascular” category generated \$1.41 million of sales in the nine months ended September 30, 2017, compared to \$1.78 million in the same period of 2016, which represented a decrease of \$0.37 million. This decrease was mainly due to the sales decrease of Alginate Sodium Diester Injection product due to market fluctuation.

Sales of the “Digestive Diseases” generated \$0.61 million and \$0.58 million in the nine months ended September 30, 2017 and 2016, respectively.

Cost of Revenue

For the nine months ended September 30, 2017, our cost of revenue was \$7.6 million, or 81% of total revenue, which represented a decrease of \$1.3 million from \$8.8 million, or 86% of total revenue, in the same period of 2016. The decrease in cost of revenue in the nine months ended September 30, 2017 was mainly due to the decrease in revenue, as well as the increase in efficiency of raw material consumption due to our machinery and equipment ran more smoothly.

Gross Margin and Gross Profit

Gross profit for the nine months ended September 30, 2017 was \$1.8 million, compared to \$1.5 million in the same period of 2016. Gross profit margin for the nine months ended September 30, 2017 and 2016 were 19% and 14%, respectively.

Selling Expenses

Our selling expenses for the nine months ended September 30, 2017 were \$2.2 million, a decrease of \$0.6 million, or 20%, compared to \$2.8 million for the same period of 2016. Selling expenses accounted for 23.6% and 26.7% of the total revenue in the first nine months of 2017 and 2016 respectively. Despite the decrease in sales, we still rely on comparable personnel and expenses to support our revenue and collection of accounts receivable. In addition, once we receive a new GMP certificate for our new building, we intended to recover our market share that requires additional selling expenses and marketing efforts.

General Administrative Expenses

Our general and administrative expenses for the nine months ended September 30, 2017 and 2016 were both \$1.4 million.

Research and Development Expenses

Our research and development expenses for the nine months ended September 30, 2017 were \$0.1 million, compared to \$0.3 million in the same period of 2016.

Bad Debt Expenses

Our bad debt expenses for the nine months ended September 30, 2017 and 2016 were both \$1.0 million. Please see additional discussion of bad debt and account receivables in the section above named “Bad Debt Benefit”. The changes

in the allowance for doubtful accounts during the nine months ended September 30, 2017 and 2016 were as follows:

	For the Nine Months Ended September 30,	
	2017	2016
Balance, Beginning of Period	\$15,664,496	\$28,644,398
Bad debt expense	954,518	1,005,949
Foreign currency translation adjustment	1,022,421	(270,150)
Balance, End of Period	\$17,641,435	\$29,380,197

Impairment of Long-Term Assets

During the nine months ended September 30, 2017, the Company reviewed the contracts relating to advances made for purchases of intangible assets with independent laboratories and determined that the advances made by the Company for three formulas to two of the independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to these laboratories in the amount of \$2.2 million. In the same period in 2016, the Company also recognized \$1.5 million impairment loss for the advances made to three laboratory for one formula per the evaluation.

Loss from Operations

Our operating loss for the nine months ended September 30, 2017 was approximately \$5.0 million, compared to \$5.1 million for the same period of 2016.

Net Loss

Our net loss for the nine months ended September 30, 2017 and 2016 was \$5.5 million and \$5.8 million, respectively, which represented an improvement of \$0.3 million.

Liquidity and Capital Resources

Our principal sources of liquidity are cash generated from operations and short-term bank loans. Our cash and cash equivalents were \$1.1 million, which represents 1.5% of our total assets as of September 30, 2017 as compared to \$2.7 million, which represents 3.4% of our total assets as of December 31, 2016. All of the \$1.1 million cash and cash equivalents as of September 30, 2017 is considered to be reinvested indefinitely in Helpson and is not expected to be available for payment of dividends, for other payments to our parent company or to its shareholders. We entered into an eight-year construction loan facility on September 21, 2013. The total loan facility amount is RMB 80 million (approximately \$13 million), which had been fully utilized through May 7, 2014. We have accumulatively repaid the principal of RMB 20 million (approximately \$3.0 million) of the construction loans per the payback schedule as of September 30, 2017. The current balance of the construction loan facility is \$2.3 million as of September 30, 2017. During July of 2017, the Company made the required payment of RMB 9 million (approximately \$1,320,000). The cash flow generated from operating activities was used to fund our daily operating expenses as well as repayment of our loan facility.

Based on our current operating plan, management believes that our cash provided by operations will be sufficient to meet our working capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions and the remaining new GMP upgrade related construction and equipment in our prior facility for the next twelve months. However, if circumstances change and we do not meet our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional financing as necessary for expansion purposes and when we believe market conditions are most advantageous, which may include debt and/or equity financing. There can be no assurance that any additional financing will be available on acceptable terms, if at all.

Operating Activities

Net cash used by operating activities was \$0.1 million in the nine months ended September 30, 2017 compared to \$1.4 million generated for the nine months ended September 30, 2016.

As of September 30, 2017, our net accounts receivable was \$2.9 million, compared to \$4.0 million as of December 31, 2016.

As of September 30, 2017, net inventory was \$6.8 million, compared to \$7.3 million as of December 31, 2016. This decrease was mainly due to the decrease in purchases in the nine months ended September 30, 2017 as compared to the nine months ended September 30, 2016.

Investing Activities

During the nine months ended September 30, 2017, net cash used in investing activities was both \$0.1 million for the nine months ended September 30, 2017 and 2016, respectively.

Financing Activities

Cash flow used in financing activities was \$1.5 million in the nine months ended September 30, 2017, which related to the payment of the construction term loan. While cash flow used in financing activities was \$3.8 million in the nine months ended September 30, 2016, which related to the payment of the construction term loan and the payment on the line of credit.

According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies' registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of September 30, 2017 and December 31, 2016, the net assets of Helpson were \$53,578,000 and \$57,461,000, respectively. Due to the restriction on dividend

distribution to overseas shareholders, the amount of Helpson's net assets that were designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, were \$8,145,000 and \$8,145,000 (50% of registered capital) for as of September 30, 2017 and December 31, 2016, respectively. Since the amount that Helpson must set aside for the statutory surplus fund only accounts for 15.2% and 14.2%, respectively, of its total net assets, this reserve does not have a major impact on our liquidity. There were no allocations to the statutory surplus reserve accounts during the nine months ended September 30, 2017.

The Chinese government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of China. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People's Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People's Bank of China. Approval of foreign currency payments by the People's Bank of China or other regulatory institutions requires the submission of a payment application form together with certain invoices and executed contracts. The currency exchange control procedures imposed by the Chinese government authorities may restrict the ability of Helpson, our Chinese subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.

Off-Balance Sheet Arrangements

As of September 30, 2017, we did not have any off-balance sheet arrangements.

Commitments

As of September 30, 2017, we were obligated to pay laboratories and others approximately \$2.8 million over the next four years upon completion of the various phases of contracts to provide CFDA production approval of medical formulas.

Critical Accounting Policies

Management's discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, "Organization and Significant Accounting Policies", is incorporated herein by reference.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2017.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 6. Exhibits

The exhibits required by this item are set forth in the Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CHINA PHARMA HOLDINGS, INC.

Date: November 14, 2017 By: /s/ Zhilin Li

Name: Zhilin Li

Title: President and Chief Executive Officer

(principal executive officer)

Date: November 14, 2017 By: /s/ Zhilin Li

Name: Zhilin Li

Title: Interim Chief Financial Officer

(principal financial officer and principal
accounting officer)

EXHIBIT INDEX

No.	Description
31.1	- <u>Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
31.2	- <u>Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
32.1	- <u>Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
101.INS	-XBRL Instance Document
101.SCH	-XBRL Taxonomy Extension Schema Document
101.CAL	-XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	-XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	-XBRL Taxonomy Extension Label Linkbase Document
101.PRE	-XBRL Taxonomy Extension Presentation Linkbase Document